Os múltiplos benefícios dos inibidores do SGLT2

• Autor(a) principal: Cabral, Ana Júlia Marinho
• Data de Publicação: 2022
• Tipo de documento: Trabalho de conclusão de curso
• Idioma: por
• Título da fonte: Repositório do Centro Universitário Braz Cubas
• Texto Completo: https://repositorio.cruzeirodosul.edu.br/handle/123456789/4143
• topic: iSGLT2; diabetes; insuficiência cardíaca; insuficiência renal crônica; CNPQ::CIENCIAS DA SAUDE::MEDICINA

Sodium-Glucose Cotransporter 2 (iSG2) Inhibitors (dapagliflozin, empaglifozin and canaglifozin) are used in the treatment of type 2 Diabetes Mellitus (DM2) but, recently, these are being used in the treatment of cardiovascular and renal drugs, adapting to the growing scientific evidence of clinical and laboratory benefits. The general objective of this study was to describe in an integrative way the importance of using SGT2 inhibitors in glycemic control and cardiovascular and renal outcomes. This is an integrative literature review, using the following databases: BVS, Pubmed and ScienceDirect during the period from March 2022 to April 2022. For the selection of articles, the following health descriptors (decs.bvs. br )” Glucose Drug Transport 2 Inhibitors”, Heart Failure”, “Chronic Kidney Disease”, “death” combined with Boolean operators “AND”. On outcomes, the 13 articles included are cohort and primary and secondary studies of multicenter, double-blind, placebo-controlled, randomized clinical trials testing the iSGT2 in different population samples. It was identified that the use of lower iSGLT2 when compared with the dipeptidyl peptidase-4 (DDP4i) inhibitor group was associated with risks of congestive heart failure (CHF), Relative Risk (RR): 0.66; 95% CI 0.49-0.89; p = 0.0062, or amputation, RR: 0.43; IC 95% 0.30-0.62; p < 0.0001 and cardiovascular death RR: 0.67; 95% CI 0.49-0.90; p = 0.0089. Another study, presented in a population with cardiac function, a study for cardiovascular death or hospitalization for heart failure, 0.75; 95% CI, 0.65 to 0.86; P<0.001. In patients with less severe renal decline, the RR is the composite of a sick patient estimated to have at least 50% decline in end-stage renal disease or death from renal causes (95% CI, 0.45 to 0.68 P< 0.001), and the risk to ratio for the composite of death from cardiovascular or cardiaccauses from cardiac dysfunction was 0.71; (95% CI, 0.5 to 0.92 P = 0.009). Completion Risk and Completion Risk Management LT2 researchers supported Completion Risk and Completion Risk Management data. In addition, the sample reduction in all-cause mortality, the delay in the loss of renal function, and also the reduction in the risk of renal compound. These are probably the SGLT2 inhibitors that are likely to play an important role in the treatment of cardiovascular and renal endocrine diseases.